USD 3.1
(-15.76%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.09 Million USD | -47.08% |
2022 | 2.06 Million USD | -0.99% |
2021 | 2.09 Million USD | 31.01% |
2020 | 1.59 Million USD | -33.94% |
2019 | 2.41 Million USD | 147.86% |
2018 | 974.58 Thousand USD | 14.9% |
2017 | 848.21 Thousand USD | -38.74% |
2016 | 1.38 Million USD | 485.62% |
2015 | 236.42 Thousand USD | 142.23% |
2014 | 97.6 Thousand USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 1.44 Million USD | 6.32% |
2024 Q1 | 1.36 Million USD | 24.41% |
2023 Q3 | 2.4 Million USD | 3.99% |
2023 FY | 1.09 Million USD | -47.08% |
2023 Q4 | 1.09 Million USD | -54.49% |
2023 Q2 | 2.31 Million USD | 7.35% |
2023 Q1 | 2.15 Million USD | 4.17% |
2022 Q3 | 2.13 Million USD | 8.32% |
2022 FY | 2.06 Million USD | -0.99% |
2022 Q4 | 2.06 Million USD | -3.26% |
2022 Q2 | 1.97 Million USD | 5.73% |
2022 Q1 | 1.86 Million USD | -10.64% |
2021 Q2 | 2.25 Million USD | 115.23% |
2021 Q1 | 1.04 Million USD | -34.41% |
2021 Q4 | 2.09 Million USD | -3.14% |
2021 FY | 2.09 Million USD | 31.01% |
2021 Q3 | 2.15 Million USD | -4.2% |
2020 Q4 | 1.59 Million USD | -21.25% |
2020 Q2 | 1.88 Million USD | 0.48% |
2020 Q1 | 1.87 Million USD | -22.3% |
2020 FY | 1.59 Million USD | -33.94% |
2020 Q3 | 2.02 Million USD | 7.45% |
2019 Q4 | 2.41 Million USD | 9.17% |
2019 Q3 | 2.21 Million USD | 61.94% |
2019 Q2 | 1.36 Million USD | 63.59% |
2019 Q1 | 835.23 Thousand USD | -14.3% |
2019 FY | 2.41 Million USD | 147.86% |
2018 Q1 | 860.19 Thousand USD | 1.41% |
2018 Q4 | 974.58 Thousand USD | -44.29% |
2018 Q2 | 1.1 Million USD | 28.45% |
2018 Q3 | 1.74 Million USD | 58.33% |
2018 FY | 974.58 Thousand USD | 14.9% |
2017 Q3 | 312.04 Thousand USD | 92.26% |
2017 Q1 | 1.92 Million USD | 39.02% |
2017 FY | 848.21 Thousand USD | -38.74% |
2017 Q4 | 848.21 Thousand USD | 171.83% |
2017 Q2 | 162.3 Thousand USD | -91.57% |
2016 Q2 | 515.92 Thousand USD | 0.0% |
2016 FY | 1.38 Million USD | 485.62% |
2016 Q4 | 1.38 Million USD | 51.33% |
2016 Q3 | 914.88 Thousand USD | 77.33% |
2016 Q1 | - USD | -100.0% |
2015 Q4 | 236.42 Thousand USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 FY | 236.42 Thousand USD | 142.23% |
2014 FY | 97.6 Thousand USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aspira Women's Health Inc. | 8.62 Million USD | 87.305% |
bioAffinity Technologies, Inc. | 3.36 Million USD | 67.467% |
Intelligent Bio Solutions Inc. | 5.59 Million USD | 80.428% |
Standard BioTools Inc. | 159.86 Million USD | 99.315% |
Inotiv, Inc. | 588.04 Million USD | 99.814% |
Prenetics Global Limited | 44.01 Million USD | 97.512% |
Neuronetics, Inc. | 81.64 Million USD | 98.659% |
Star Equity Holdings, Inc. | 21.67 Million USD | 94.947% |
Castle Biosciences, Inc. | 86.54 Million USD | 98.735% |
Psychemedics Corporation | 6.59 Million USD | 83.402% |
RadNet, Inc. | 2.07 Billion USD | 99.947% |
Exact Sciences Corporation | 3.32 Billion USD | 99.967% |
IDEXX Laboratories, Inc. | 1.77 Billion USD | 99.938% |
iSpecimen Inc. | 6.07 Million USD | 81.982% |
OpGen, Inc. | 13.44 Million USD | 91.854% |
Exagen Inc. | 34.25 Million USD | 96.802% |
Bionano Genomics, Inc. | 118.24 Million USD | 99.074% |
CareDx, Inc | 223.28 Million USD | 99.51% |
Check-Cap Ltd. | 1.33 Million USD | 17.657% |
Twist Bioscience Corporation | 152.97 Million USD | 99.284% |
Guardant Health, Inc. | 1.62 Billion USD | 99.933% |
Biodesix, Inc. | 94.51 Million USD | 98.841% |
BioNexus Gene Lab Corp. | 1.74 Million USD | 37.13% |
Precipio, Inc. | 3.67 Million USD | 70.175% |
Natera, Inc. | 691.79 Million USD | 99.842% |
Fulgent Genetics, Inc. | 139.82 Million USD | 99.217% |
Sera Prognostics, Inc. | 25.28 Million USD | 95.668% |
23andMe Holding Co. | 206.64 Million USD | 99.47% |
OPKO Health, Inc. | 622.47 Million USD | 99.824% |
Personalis, Inc. | 95.65 Million USD | 98.855% |
Aclaris Therapeutics, Inc. | 40.22 Million USD | 97.277% |
Applied DNA Sciences, Inc. | 8.77 Million USD | 87.525% |
T2 Biosystems, Inc. | 62.83 Million USD | 98.257% |
Neogen Corporation | 1.44 Billion USD | 99.924% |
Myriad Genetics, Inc. | 312.9 Million USD | 99.65% |
ICON Public Limited Company | 7.74 Billion USD | 99.986% |
NeoGenomics, Inc. | 739.69 Million USD | 99.852% |
Star Equity Holdings, Inc. | 21.67 Million USD | 94.947% |
MDxHealth SA | 121.92 Million USD | 99.102% |
Prenetics Global Limited | 44.01 Million USD | 97.512% |
Illumina, Inc. | 4.36 Billion USD | 99.975% |
DarioHealth Corp. | 38.24 Million USD | 97.136% |
Medpace Holdings, Inc. | 1.09 Billion USD | 99.9% |
Mainz Biomed B.V. | 12.15 Million USD | 90.994% |
Trinity Biotech plc | 83.38 Million USD | 98.687% |
Sotera Health Company | 2.68 Billion USD | 99.959% |
bioAffinity Technologies, Inc. | 3.36 Million USD | 67.467% |